					s	heet 1 of 1	
				ATTY DOCKET NO.		APPLICATION NO	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)  U.S. PATENT DOCUM			10271-048-999		09/996,265		
			APPLICANT				
			Young et al.				
			FILING DATE		GROUP		
			November 28, 2001		1648		
,	U.S. PA	ATENT DOCUM	ENTS				
DOCUMENT NUMBER	DATE		VAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	8/17/99	Brams et al.					
5,811,524	9/22/98	Brams et al.	·				
				<u> </u>			
					<b>-</b>		
					<b></b>		
_			<del></del>		-		
					<u> </u>	<u> </u>	
	FOREIGN	PATENT DOC	UMENTS				
DOCUMENT NUMBER	DATE	COU	NTRY ·	CLASS	SUBCLASS	TRANSLATION	
WO 96/05229	2/22/96	PCT		T		YES NO	
-	<del> </del>	1		<del>                                     </del>			
	<del>                                     </del>						
		~					
				. D			
OTHER REFER	•	*					
Hacking et al., 2002, "	Respiratory syn	ncytial virus - viral bi	ology and the host re	esponse," J	Infection 45		
Hacking et al., 2002, "To Heard et al., 1999, "To	Respiratory syn	ncytial virus - viral bi	ology and the host re	esponse," J	Infection 45		
Hacking et al., 2002, "To Heard et al., 1999, "To 5:35-45	Respiratory syn	ncytial virus - viral bi human RSV antibodi acted loghilized paliv	ology and the host rules: cloning, express	esponse," J.	. Infection 45	n," Mol. Med.	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe	Respiratory syn wo neutralizing tion of reconstit at. Dis. 166A: 97. "Phase VIII	human RSV antibodi human RSV antibodi arted loghilized paliv 969 (April 1	ology and the host relies: cloning, express izumab given intraver 9 19 )	esponse," J. ion, and chi enously at 1	Infection 45 aracterization  5 and 30 mg	n," Mol. Med.  /kg," Poster  synctial virus	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal and	Respiratory syn wo neutralizing tion of reconstite et. Dis. 166A: 9 97, "Phase I/II tibody (Medi-49	human RSV antibodi human RSV antibodi arted loghilized paliv 969 (April 1	ology and the host relies: cloning, express izumab given intraver 9 19 )	esponse," J. ion, and chi enously at 1	Infection 45 aracterization  5 and 30 mg	n," Mol. Med.  /kg," Poster  synctial virus	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal ant HIV virology, ICAAC	Respiratory syn wo neutralizing ion of reconstit ict. Dis. 166A: 9 97, "Phase VII of tibody (Medi-49 Toronto	human RSV antibodi human RSV antibodi atted loghilized palivi 969 APVIII open label multi dose 93) administered intra	ology and the host relies: cloning, express izumab given inuave 9 19) e escalation trial of a amuscularly (IM) in the controlled dose	esponse," J. ion, and chi enously at 1 humanized high risk cl	Infection 45 aracterization 3 and 30 mg I respiratory nildren," Abs	n," Mol. Med.  /kg," Poster  synctial virus stracts in Non  anized	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal ant HIV virology, ICAAC Subramanian et al., 19 respiratory synctial virology synctial virology."	Respiratory syn wo neutralizing ion of reconstit at. Dis. 166A: 9 97, "Phase VII bibody (Medi-49 Toronto 197, "Randomiz rus monoclonal	human RSV antibodi human RSV antibodi arted lonhilized paliv 1969 A Drill open label multi dose 1930 administered intra ted double blind place antibody in hugh risl	ology and the host relies: cloning, express izumab given intravel 9 19 ) e escalation trial of a amuscularly (IM) in the controlled dose in fants," Poster se	esponse," J. ion, and chi enously at 1 humanized high risk cl	Infection 45 aracterization 3 and 30 mg I respiratory nildren," Abs	n," Mol. Med.  /kg," Poster  synctial virus stracts in Non  anized	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal ant HIV virology, ICAAC Subramanian et al., 19 respiratory synctial vir Sorbera et al., 1998, "I	Respiratory syn wo neutralizing from of reconstite et. Dis. 166A: 9 97, "Phase I/II tibody (Medi-49 Toronto 197, "Randomiz rus monoclonal Palivizumab," I	human RSV antibodi atted loghilized paliv 969 April 1 open label multi dose 93) administered intra- ted double blind place antibody in hugh risl Drugs of the Future 2	ology and the host relies: cloning, express izumab given intrave 9 19 escalation trial of a amuscularly (IM) in the controlled dose k infants," Poster set 3:970-976	esponse," J. ion, and chi enously at 1 humanized high risk cl	Infection 45 aracterization 3 and 30 mg I respiratory nildren," Abs	n," Mol. Med.  /kg," Poster  synctial virus stracts in Non  anized	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal ant HIV virology, ICAAC Subramanian et al., 19 respiratory synctial virology.	Respiratory syn wo neutralizing from of reconstite et. Dis. 166A: 9 97, "Phase I/II tibody (Medi-49 Toronto 197, "Randomiz rus monoclonal Palivizumab," I	human RSV antibodi atted loghilized paliv 969 April 1 open label multi dose 93) administered intra- ted double blind place antibody in hugh risl Drugs of the Future 2	ology and the host relies: cloning, express izumab given intrave 9 19 escalation trial of a amuscularly (IM) in the controlled dose k infants," Poster set 3:970-976	esponse," J. ion, and chi enously at 1 humanized high risk cl	Infection 45 aracterization 3 and 30 mg I respiratory nildren," Abs	n," Mol. Med.  /kg," Poster  synctial virus stracts in Non  anized	
Hacking et al., 2002, "To 5:35-45 Landry et al., "Evaluat Session, Tuesday, Infe Saez-Llorens et al., 19 (RSV) monoclonal ant HIV virology, ICAAC Subramanian et al., 19 respiratory synctial vir Sorbera et al., 1998, "I	Respiratory syn wo neutralizing into of reconstitute. Dis. 166A: 997, "Phase VIII of thoody (Medi-49)." Toronto 1997, "Randomiz rus monoclonal Palivizumab," I	human RSV antibodi atted loghilized paliv 969 April 1 open label multi dose 93) administered intra- ted double blind place antibody in hugh risl Drugs of the Future 2	ology and the host relies: cloning, express izumab given intrave 9 19 ) e escalation trial of a amuscularly (IM) in ebo controlled dose k infants," Poster set 3:970-976 0:702-703	esponse," J. ion, and chi enously at 1 humanized high risk cl escalation to ssion infect	Infection 45 aracterization 3 and 30 mg I respiratory nildren," Abs	n," Mol. Med.  /kg," Poster  synctial virus stracts in Non  anized 68	
	DOCUMENT NUMBER  5,939,068  5,811,524  DOCUMENT NUMBER	DOCUMENT NUMBER DATE 5,939,068 8/17/99  1 5,811,524 9/22/98  FOREIGN  DOCUMENT NUMBER DATE	U.S. PATENT DOCUM  DOCUMENT NUMBER DATE  DOCUMENT NUMBER  DATE  COL	RENCES CITED BY APPLICANT (Use several sheets if necessary)  PILING DATE November 28, 2  U.S. PATENT DOCUMENTS  DOCUMENT NUMBER DATE NAME 1, 5,939,068 8/17/99 Brams et al.  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER COUNTRY	RENCES CITED BY APPLICANT (Use several sheets if necessary)  U.S. PATENT DOCUMENTS  DOCUMENT NUMBER DATE NAME CLASS 1, 5,939,068 8/17/99 Brams et al.  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE NAME CLASS CLASS CLASS CLASS CLASS COUNTY CLASS	RENCES CITED BY APPLICANT (Use several sheets if necessary)  Voung et al.  FILING DATE NOVEMBER 28, 2001  DOCUMENT NUMBER DATE NAME CLASS SUBCLASS  5,939,068  8/17/99  Brams et al.  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DOCUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER SUBCLASS SUBCLASS  FOREIGN PATENT DOCUMENTS	

BEST AVAILABLE COPY

NY2: 1487649.1